HD17 for Intermediate Stage Hodgkin Lymphoma

• Status: Completed
• Trial end date: 2020-03-23
• Target enrollment: 0
• Participant gender: All

Summary

This study is designed to test the non-inferiority of the experimental arm compared to the standard arm in terms of progression free survival (PFS).

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Cologne
• Treatments: Bleomycin; Cyclophosphamide; Dacarbazine; Doxorubicin; Etoposide; Liposomal doxorubicin; Prednisone; Procarbazine; Vinblastine; Vincristine

Criteria

Inclusion Criteria:

• Hodgkin Lymphoma

• CS I, II with risk factor (stage IIB with risk factor 1 or 2 are not included)

• large mediastinal mass (>1/3 of maximum transverse thorax diameter)

• extranodal involvement

• elevated ESR

• 3 or more involved nodal areas

• written informed consent

Exclusion Criteria:

• Leucocytes <3000/µl

• Platelets < 100000/µl

• Hodgkin Lymphoma as composite lymphoma

• Activity Index (WHO) >2